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Summary 
Factors influencing T-cell responses are important for vaccine development but incompletely 
understood. Here vaccinia virus (VACV) protein N1 is shown to impair the development of both 
effector and memory CD8+ T-cells and this correlates with its inhibition of nuclear factor kappa B 
(NF-κB) activation. Infection with VACVs that either have the N1L gene deleted (vΔN1) or 
containing an I6E mutation (vN1.I6E) that abrogates its inhibition of NF-κB resulted in increased 
central and memory CD8+ T-cell populations, increased CD8+ T-cell cytotoxicity and lower virus titres 
after challenge. Furthermore, CD8+ memory T-cell function was increased following infection with 
vN1.I6E, with more IFNγ production and greater protection against VACV infection following passive 
transfer to naïve mice, compared to CD8+ T-cells from mice infected with wild type virus (vN1.WT). 
This demonstrates the importance of NF-κB activation within infected cells for long-term CD8+ T-cell 
memory and vaccine efficacy. Further, it provides a rationale for deleting N1 from VACV vectors to 
enhance CD8+ T-cell immunogenicity, while simultaneously reducing virulence to improve vaccine 
safety. 
 
Introduction 
Immunological memory provides protection against reinfection by pathogens encountered previously 
and in mammals is conferred by specific leukocyte populations that endure long after clearance of 
infection [1, 2]. Naïve T-cell clones expand rapidly after T-cell receptor ligation and, whilst most die 
subsequently after clearance of the specific antigen, some survive to become long-lasting memory 
cells that protect against future infection [3, 4]. Induction of strong T-cell memory is desirable for 
vaccine development but factors that influence this are not fully understood. Two populations of 
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memory T-cells, called central and effector memory CD8+ and CD4+ T-cells (TCM and TEM 
respectively), are defined by expression of specific surface markers. In mice these are CD62L and 
CD44 (TCM being CD44hiCD62Lhi and TEM being CD44hiCD62Llo) and are induced well by acute viral 
infections [5, 6]. These subsets are functionally distinct because TCM cells mediate long term 
protection, whilst TEM cells provide immediate protection [6] and they have distinct locations with 
TCM being resident mainly in lymph nodes, whilst TEM are predominantly in peripheral tissue. CD8+ 
TCM and TEM cells confer protection against several pathogens, although the TCM subset may be more 
broadly protective [7-10]. 
 
Vaccinia virus (VACV) was the live vaccine used to eradicate smallpox [11] and induces long-lasting 
protective immunity [12-15], for review see [16]. Consequently, VACV is useful for studying the 
induction of immunological memory. Moreover, the engineering of VACV to express foreign antigens 
has made VACV a popular vector for vaccine development [17, 18]. VACV expresses about 200 
proteins [19] and many of these inhibit innate immunity [20]. Studying such immunosuppressive 
proteins provides insight into how the innate immune system functions and may be suppressed 
[21-23], and their manipulation can improve VACV immunogenicity. For instance, deletion of genes 
encoding the chemokine binding protein A41 [24], the IL-1β binding protein B15 [25], or the IRF3 
inhibitor C6 enhanced immune responses [26, 27]. Such viruses are useful tools for studying how the 
innate immune response shapes adaptive immunity [28]. 
 
This paper concerns VACV protein N1 and shows that its deletion or mutation can simultaneously 
reduce virus virulence and induce stronger CD8+ T-cell responses that confer enhanced protection 
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against virus challenge. N1 is present in many, but not all, VACV strains and orthopoxviruses, for 
details see reference [29], and is, for instance, present in VACV strain modified virus Ankara (MVA) 
but is shortened from 117 to 113 amino acid residues due to a frameshift mutation that removes the 
last 27 residues and replaces these with 23 unrelated residues [30]. N1 is an intracellular homodimer 
expressed early during infection [29] that inhibits activation of NF-κB [31-33], suppresses apoptosis 
[33, 34] and contributes to virus virulence [29, 33, 35]. The crystal structure of N1 revealed a Bcl-2 
fold [34, 36] and structure-based mutagenesis showed that inhibition of NF-κB activation and 
apoptosis are separable [33]. N1 mutants unable to block NF-κB activation (I6E) or apoptosis (R58Y 
and Q61Y) were described and analysis of recombinant VACVs expressing these mutant N1 proteins 
showed that inhibition of NF-κB activation, rather than apoptosis, was the predominant mechanism by 
which protein N1 contributed to VACV virulence [33]. An additional mutant, R71Y, affected neither 
inhibition of apoptosis nor NF-κB activation and a virus bearing this mutation has wild type virulence 
[33]. 
 
Here, these VACVs are utilised to study how NF-κB activation during infection influences 
development of cellular immunity, immunological memory and resistance to reinfection. NF-κB is 
crucial in regulating inflammation and cell proliferation, but there is little direct evidence of its role in 
development of immunological memory due to gross developmental defects in mice where NF-κB 
signalling is suppressed. Recombinant VACVs with altered ability to suppress NF-κB enable 
circumvention of this problem. Data presented show that intradermal (i.d.) infection with VACV 
lacking N1 (vΔN1) or bearing the I6E mutation (vN1.I6E) caused increased activation of CD8+ T-cells 
compared to WT virus (vN1.WT), illustrating the importance of NF-κB signalling for induction of 
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T-cell responses. Furthermore, mice infected with vN1.I6E or vΔN1 developed increased numbers of 
CD8+ TCM and TEM cells that mediated enhanced protected against VACV challenge. This study 
illustrates how the innate immune response to viral infection driven by NF-κB has a profound impact 
on the development of T-cell memory and provides a rationale for deleting the N1L gene, and possibly 
other inhibitors of NF-κB, from VACV-based vaccines. 
 
Materials and Methods 
Ethics statement 
This work was conducted under licence PPL 70/7116 from United Kingdom Home Office according 
to the Animals (Scientific Procedures) Act 1986. 
 
Mice and cell lines 
Female C57BL/6 (B6) mice (Harlan) were housed under pathogen-free conditions. EL4 (H-2b) and 
P815 (H-2d) cells (both ATCC) were cultured in RPMI 1640 (Gibco) containing 10% foetal bovine 
serum (FBS) (Harlan Seralab) and penicillin/streptomycin (50 µg/ml; Gibco). 
 
Viruses 
VACV strain WR recombinants vN1.WT and vΔN1 [29] and VACVs expressing N1 mutant protein 
I6E, R58Y, Q61Y and R71Y were described [33]. Virus infectivity was titrated by plaque assay on 
BSC-1 cells. 
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Murine infection models 
Female C57BL/6 mice (6-8 weeks) were infected i.d. with 104 plaque-forming units (PFU) in both ear 
pinnae [37, 38]. Virus doses used to infect animals were always re-titrated to confirm the infectious 
dose administered. In vivo data shown are from one representative experiment, and all experiments 
were performed at least twice. To determine virus titres, infected ears were ground with a tissue 
homogenizer, subjected to three cycles of freezing and thawing and sonication, and the resulting 
homogenate was titrated on BSC-1 cells [37, 38]. To evaluate the degree of protection induced by i.d. 
infection, immunised mice were challenged by i.n. infection with the indicated dose of VACV strain 
WR as described [39]. 
 
Isolation of cell populations 
Mice were euthanised and the liver, spleen, lung and lymph nodes were removed. Hepatic 
lymphocytes were prepared as described [40]. Splenocytes and lymph node suspension cells were 
obtained by forcing the organ through a stainless steel mesh. Splenocytes were treated with 0.2% 
NaCl solution to remove erythrocytes. Lung pieces were incubated in RPMI 1640 with 5% FBS, 100 
U/ml penicillin/streptomycin, 10 mM HEPES, 50 μM 2-ME, 20 mM L-glutamine containing 20 U/ml 
collagenase (Type Ia) and 1 μg/ml DNase (Type I) for 30 min prior to passing through a mesh. For 
preparation of cells for passive transfer to recipient mice, the mouse CD4+ or CD8+ T-cell isolation kit 
was used as indicated by the manufacturer (Miltenyi Biotec) to deplete non-CD4+ or non-CD8+ cells 
on an autoMACS instrument. 
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Antibodies, cell staining and flow cytometry 
Anti-mouse CD3 (clone 145-2C11), CD4 (GK1.5), CD8 (5H10-1), B220 (RA3-6B2), NK1.1 (PK136), 
CD11b (M1/70), Ly-6G/Ly-6C (RB6-8C5), CD44 (IM7), CD62L (MEL-14), granzyme B (GB11), 
CD16/32 (2.4G2) and IFN-γ (XMG1.2) mAb were purchased from BD Biosciences or Biolegend. The 
mAbs were purified or conjugated with FITC, PerCP/cy5.5, APC, PE-Cy7, BV650 C or BV421. 
Isotype controls were used as negative controls. For intracellular staining, cells were incubated with 
Golgistop (BD Pharmingen) for 5 h before analysis. After surface staining, samples were fixed, 
permeabilised using Cytofix/Cytoperm intracellular staining kit (BD Pharmingen), and incubated with 
the indicated mAb. Then cells were stained intracellularly for 30 min, washed and fixed in 1% 
paraformaldehyde (Sigma-Aldrich). Flow cytometry was performed with a BD LSR Fortessa (BD 
Biosciences), and data were analysed with FlowJo software (Tree Star Inc.). LIVE/DEAD® Fixable 
Aqua Dead Cell Stain Kit (Life Technologies) was used to exclude nonviable cells from analysis. 
 
DimerX assay to detect VACV specific CD8+ T-cells 
Recombinant soluble dimeric mouse H-2Kb:Ig fusion proteins were purchased from BD Biosciences 
and the DimerX assay was performed according to the manufacturer’s instructions. Briefly, 2 µg of 
H-2Kb:Ig fusion proteins were incubated overnight at 37°C in PBS with a 40 molar excess of B820 
peptide (TSYKFESV). Peptide-loaded dimers were then incubated for 1 h at room temperature with 
PE-coupled anti-mouse IgG1 (clone A85-1, BD Biosciences). Cells were labelled with DimerX and 
anti-CD8 (clone 53-6.7, BD Biosciences) for 1 h on ice and washed twice before acquisition using a 
BD LSR Fortessa (BD Biosciences). Analysis was done using FlowJo software (Tree Star Inc.). 
Events were gated for live lymphocytes on FCS × SSC followed by CD8+ T-cells × DimerX+ cells. 
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Backgrounds as determined using irrelevant peptides were in the order of 0.5 to 0.8% and were 
subtracted from the values presented for test samples. 
 
51Cr release cytotoxic assay 
Cytotoxic T lymphocyte (CTL) activity was assayed by 51Cr-release assay [24]. VACV-infected EL4 
cells were used as targets for VACV-specific CTL lysis. In some experiments, CD8+ cells were 
depleted from liver and spleen cell suspensions by incubation with anti-CD8 mAb (clone 3.115) 
together with human complement. An isotype control mAb was used in parallel. Flow cytometry 
confirmed >95% depletion of the desired cells. The remaining cells were used for cytotoxicity assays 
without adjustment for alteration in number during depletion. The cytotoxicity of purified NK cells 
was tested on VACV-infected P815 cells by 51Cr release assay. The percentage of specific 51Cr release 
was calculated as specific lysis  =  [(experimental release−spontaneous release)/(total detergent 
release−spontaneous release)]×100. The spontaneous release values were always <15% of total lysis.  
 
Cell depletion by antibody in vivo 
Rat anti-CD8 (YTS169) or rat anti-CD4 (YTS 191.1) mAbs were concentrated from tissue culture 
supernatant by ammonium sulphate precipitation and quantified by ELISA. Depleting antibodies (0.3 
mg) were injected into the peritoneal cavity of naïve recipient mice 10, 8 and 6 days prior to transfer 
of 106 CD8+ or CD4+ T-cells from immunised or naïve mice. The depletion of specific T-cell 
populations was analysed by FACS and showed >95% of specific cells were depleted. 
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Serum antibody titration 
To measure the neutralising titre of anti-VACV antibodies, vaccinated mice were exsanguinated at 28 
day p.i., and sera were prepared and heated at 56 ºC for 30 min to inactivate complement. Two-fold 
dilutions of sera in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 2% 
FBSwere prepared and were incubated with VACV intracellular mature virus (purified by sucrose 
density gradient centrifugation) for 1 h at 37 ºC before plaque assay on BS-C-1 cells. ND50 values 
represent the reciprocal of the serum dilution giving 50% reduction in plaque number compared to 
virus incubated without serum. 
 
Statistical analyses 
Data were analysed using GraphPad Prism 5 software, represented as mean with the standard error of 
the mean (SEM), and assessed for significance using the Mann–Whitney U or student's t-test statistics. 
p-values less than 0.05 were considered statistically significant. *< 0.05, **< 0.01. 
 
Results 
Deletion of VACV N1 increases effector CD8+ T-cell numbers during acute infection 
Intradermal infection with vN1.WT, vΔN1 or viruses with single amino acid mutations in the N1 
protein did not affect virus replication in vivo early (2 days) post infection p.i. (Supplementary Figure 
1), as noted earlier for vN1.WT, vΔN1 or revertant viruses [29]. To investigate if blocking NF-κB or 
apoptosis affected virus immunogenicity, mice were immunised i.d. with these viruses to mimic 
dermal vaccination and splenic T-cells were analysed one month thereafter. Total splenic cells 
increased substantially early after infection (being maximal 7-10 days p.i.), but there were no 
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differences between vN1.WT and the N1 mutant viruses in the magnitude or kinetics of this response 
(Figure 1A, B). The absolute numbers of T-cells (CD3+CD4+, CD3+CD8+), B cells (CD3-B220+) and 
NK cells (CD3-NK1.1+) in the spleen at 7 days p.i. increased after infection (Figure 1C), but no 
differences were observed between the viruses. The proportion of splenic T-cells (expressed as a 
percentage of total lymphocytes) increased after infection, whereas this value decreased for B cells 
(Figure 1D). The proportions of splenic macrophages (CD11b+Ly6G-) and neutrophils (CD11b+Ly6G+) 
(not shown) were similar to mock infection for all viruses. Analysis of cells in the posterior cervical 
lymph nodes proximal to the infection site showed similar results for the total cell numbers 
(Supplementary Figure 2A), CD8+ T-cells (Supplementary Figure 2B) and other cell subsets including 
CD4+ T-cells, B cells, NK cells, macrophages and neutrophils (not shown). 
 
During acute VACV infection activated CD8+ T-cells have high granzyme B (GzmB) and low CD62L 
expression (GzmBhiCD62Llo) and this population can be detected without the requirement for ex vivo 
peptide antigen stimulation [41]. These cells were analysed at different times p.i and in naïve mice, 
~95% of splenic CD8+ T-cells were in the resting, GzmBloCD62Lhi, population and less than 1% were 
GzmBhiCD62Llo. However, 7 days p.i. with vN1.WT, vN1.R58Y or vN1.R71Y approximately 45% of 
splenic CD8+ T-cells were GzmBhiCD62Llo. Notably, after infection with vΔN1 or vN1.I6E this 
population increased to >60% and the differences between these viruses and vN1.WT, vN1.58Y and 
vN1.R71Y were statistically significant (Figure 2A, B). Similar results were obtained 14 days p.i. 
when vΔN1 and vN1.I6E caused an increased proportion of activated CD8+ T-cells. By days 21 and 
28 p.i. the activated CD8+ T-cell population had decreased to resting levels in all groups (Figure 2). In 
conclusion, deletion of N1 or I6E mutation increased the number of activated CD8+ splenocytes 
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(Figure 2B). To quantify VACV-specific CD8+ T-cells, DimerX reagent loaded with the 
immunodominant VACV B820-27 peptide was used. Consistent with a previous study [41], 
VACV-specific GzmBhiCD62Llo CD8+ T-cells were identified in the spleen at day 7 p.i., and their 
proportion and absolute number increased upon deletion of N1 or I6E mutation (Figure 3A, B). In the 
draining lymph nodes this difference was more pronounced (p<0.01) (Figure 4). Therefore, either 
removal of N1, or its mutation to ablate inhibition of NF-κB, induced greater numbers of CD8+ 
effector T-cells following infection. 
 
VACVΔN1 induces enhanced development of immunological memory  
To test if changes induced by N1 mutation influenced protection against reinfection, mice were 
immunised i.d. with WT or mutant viruses and challenged i.n. 4 weeks later (when activated CD8+ 
T-cells had returned to resting levels) with a dose of VACV WR (5×106 p.f.u) representing >200 LD50 
for naïve mice [29, 42]. Mice vaccinated with vΔN1 or vN1.I6E showed better protection against 
challenge, characterised by reduced weight loss and more rapid recovery, compared to those 
immunised with vN1.WT, vN1.R58Y or vN1.R71Y (Figure 5A). Also, the virus titre in lungs 4 days 
after virus challenge was lower following immunisation with vΔN1 or vN1.I6E compared to other 
groups (Figure 5B). No virus was detected in spleen after challenge for any of the virus groups (data 
not shown). Collectively, although deletion or I6E mutation of N1 reduced virulence, these changes 
enhanced immunological memory following vaccination. 
 
To understand the basis of enhanced protection, VACV-specific antibodies were measured at 28 days 
p.i by plaque reduction neutralisation assay [43]. This showed that all groups of immunised mice had 
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high serum antibody titres, but titres induced by immunisation with vΔN1 or vN1.I6E were lower 
(p<0.05) than mice infected with vN1.WT or vN1.R58Y and vN1.R71Y (Figure 5C). Therefore, 
antibody responses did not explain the enhanced protection induced by vΔN1 and vN1.I6E, 
suggesting cellular immunity might be responsible. 
 
Deletion of VACV N1 results in enhanced CD8+ T-cell effector functions 
To investigate T-cell effector functions, the killing activity of CD8+ T-cells was assessed 28 days p.i 
with vN1.WT or the mutant N1 viruses by ex vivo cytotoxicity assay (Figure 6A). Splenic 
lymphocytes from mice immunised with vΔN1 or vN1.I6E showed significantly higher cytotoxicity 
against VACV-infected autologous target cells compared with cells derived from mice immunised 
with vN1.WT, vN1.R58Y or vN1.R71Y (Figure 6A). Notably, differences between groups and the 
cytotoxicity of lymphocytes were abolished by CD8+ T-cell depletion with specific mAb (Figure 6B). 
Analysis of hepatic lymphocytes gave similar results (not shown). Consistent with their enhanced 
killing activity, splenic CD8+ T-cells expressed significantly greater CD107a at 28 days p.i. with 
vΔN1 or vN1.I6E (p<0.01) than with vN1.WT, vN1.R58Y or vN1.R71Y (Figure 6C). NK cell 
responses were not responsible for the enhanced protection because, although splenic NK cells from 
immunised mice lysed VACV-infected targets better than mock-infected cells, there were no 
differences between mice immunised with vN1.WT or vΔN1 (Figure 6D).  
 
vΔN1 and vN1.I6E induce increased populations of CD8+ TCM and TEM cells 
The enhanced cytotoxicity of CD8+ T-cells 28 d p.i. with vΔN1 and vN1.I6E indicated phenotypic 
differences between these cells and those from mice infected with the other viruses despite activation 
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markers having returned to baseline by day 21 p.i. (Figure 2). Therefore, CD8+ TCM and TEM cells in 
the spleen and draining lymph node were analysed 28 d after i.d. infection. After vN1.I6E infection 
10.4±1.5% of splenic CD8+ T-cells were CD44hiCD62Llo (TEM) and 20.6±1.9% were CD44hiCD62Lhi 
(TCM) and similar results were obtained with vΔN1. However, only 7.1±1.3% CD8+ TEM and 
14.7±2.2% of CD8+ TCM cells were induced by vN1.WT, vN1.R58Y or vN1.R71Y and the differences 
between these groups and the vN1.I6E/vΔN1 groups were statistically significant (p<0.05) (Figure 
7A). In the draining lymph nodes this enhancement was even more pronounced (p<0.01) (Figure 7B). 
In contrast, CD4+ TCM and TEM populations were indistinguishable between viruses (Figure 7A, B). 
Analysis by DimerX staining demonstrated a higher proportion and absolute number of 
VACV-specific CD8+ T (DimerX+CD8+) cells at 28 days p.i. with vΔN1 and vN1.I6E compared to 
vN1.WT, vN1.R58Y or vN1.R71Y (p<0.05) (Figure 8A, B). In this population there were no naïve 
T-cells (CD44loCD62Lhi) and only TEM and TCM remained (Figure 8A lower panels). Infection with 
vΔN1 or vN1.I6E induced greater numbers of TEM and TCM cells than vN1.WT, vN1.R58Y or 
vN1.R71Y (p<0.05) (Figure 8C). In conclusion, N1 reduces development of CD8+ T-cell central and 
effector memory and this correlates with inhibition of NF-κB. 
 
CD8+ T-cell effector functions are enhanced after challenge of vΔN1- or vN1.I6E-vaccinated 
mice 
To address if enhanced CD8+ T-cell memory influences their effector function, IFN-γ production by 
these cells was investigated 4 days after reinfection. Cells from lungs and spleen were stimulated with 
peptides from VACV protein B8 (the IFN-γ receptor [44]) that are recognised by MHC class I 
restricted CD8+ T-cells [45] and IFN-γ production was quantified by intracellular cytokine staining. 
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IFN-γ production by cells from both organs was higher following vΔN1 and vN1.I6E infection 
compared to other viruses (Figure 9). Similar data were obtained with CD8+ T-cells from the draining 
lymph nodes (data not shown). Therefore, CD8+ T-cell memory induced by vΔN1 or vN1.I6E 
infection correlates with enhanced effector function of these cells in response to secondary infection. 
 
CD8+ T-cells from vN1.I6E-vaccinated mice confer enhanced protection  
Finally, the ability of T-cell subsets to confer protection against challenge with VACV was examined 
by passive transfer. Splenic CD8+ and CD4+ T-cells were purified from naïve or vaccinated mice 28 d 
p.i. and transferred to naïve mice that were challenged with VACV. Mice infused with an equivalent 
number of additional naïve CD8+ or CD4+ T-cells were equally susceptible to subsequent virus 
challenge (data not shown), showing that more naïve cells per se did not influence outcome. However, 
mice that received CD8+ or CD4+ T-cells from vN1.WT immunised mice responded differently to 
challenge. First, these animals lost weight sooner than mice receiving naïve cells (Figure 10). This 
effect has been observed repeatedly following i.n. challenge of VACV immunised mice and was 
attributable to lung immune pathology [24-26]. Passive transfer of anti-VACV Ab prior to challenge 
did not enhance disease symptoms [46], suggesting the effect was via cellular immunity. Figure 10 
shows this phenomenon is mediated by T-cells and that CD8+ cells play a greater role than CD4+ cells. 
Second, mice receiving either CD8+ or CD4+ T-cells from immunised mice were protected better than 
those that received equivalent cells from naïve mice, and this was characterised by a lower weight loss, 
lower virus titres and more rapid recovery (Figure 10A). Notably, the transfer of CD8+ T-cells from 
mice immunised with vN1.I6E enhanced this protection, and reduced virus titres further, whilst the 
transfer of CD4+ T-cells from these mice conferred no additional benefit over those from vN1.WT 
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immunised mice (Figure 10A). 
 
This beneficial effect of CD8+ T-cells from vN1.I6E immunised mice was also seen if the recipient 
mice were depleted of CD8+ T-cells by addition of mAb prior to passive transfer (Figure 10B). Flow 
cytometry showed that this treatment had depleted >95% of CD8+ T-cells at the time of challenge, and 
the mAb had declined to levels unable to affect the function of infused CD8+ T-cells upon transfer (A 
Cooke, personal communication). As above, CD8+ T-cells from vN1.I6E immunised mice conferred 
greater protection than cells from vN1.WT immunised mice, but the N1.I6E mutation did not 
influence protection from CD4+ cells (Figure 10A, B). Therefore, CD8+ and CD4+ memory T-cell 
populations confer protection against VACV challenge and the I6E mutation enhances protection from 
the CD8+ population. Hence, the inhibition of NF-κB by N1 correlates with a profound and specific 
effect on the generation of CD8+ T-cell memory. 
 
Discussion 
Despite encoding scores of immunomodulatory proteins, deletion of individual VACV genes can 
impact on virulence and immunogenicity [20]. Previous studies showed VACV protein N1, or its 
ectromelia virus counterpart, contributed to virulence in several infection models [29, 35, 47-49], 
affected T-cell and NK cell responses during primary infection [47, 48] and a N1 deletion mutant 
induced better protection from challenge [49]. However, it was unknown if these effects of N1 were 
attributable to inhibition of apoptosis or NF-κB or both activities, whether this phenotype was evident 
following immunisation by dermal vaccination and challenge via a heterologous route, and what 
mechanism mediated the enhanced protection. Subsequently, using VACV N1 mutants that 
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discriminate between inhibition of apoptosis and NF-κB, it was shown that virulence correlated with 
inhibition of NF-κB [33]. Here, these mutants were used to investigate the consequence of inhibiting 
NF-κB on the development of adaptive immunity using i.d. infection, mimicking dermal vaccination. 
N1 is shown to hinder the development of CD8+ T-cell effector and memory functions and this 
correlates with its ability to block NF-κB activation. 
 
During primary infection with VACV, deletion of N1 or an I6E mutation resulted in enhanced CD8+ 
T-cell (but not CD4+ or NK) cytotoxicity, increased numbers of CD8+ (but not CD4+) TCM and TEM 
cells, and better protection against challenge with VACV. In contrast, mutation of the BH3 binding 
groove of N1, which obviated the ability of N1 to bind Bad and Bid and to disrupt apoptotic signalling 
[33], did not affect T-cell responses. Therefore, N1 influences immunological memory, specifically 
CD8+ T-cells, and this correlates with inhibition of NF-κB signalling. Passive transfer demonstrated 
that CD8+ and CD4+ T-cells from immunised mice provided protection against VACV challenge, but 
CD8+ T-cells transferred from vN1.I6E-immunised mice conferred enhanced protection compared to 
CD8+ T-cells from vN1.WT-immunised mice. Therefore, enhancement of the CD8+ T-cell response 
correlates with loss of NF-κB inhibition. 
 
During acute virus infection the inflammatory environment influences the proliferation and 
development of effector and memory T-cell populations. Inflammation is the third signal required for 
optimal T-cell activation, where antigen stimulation and co-stimulation comprise signals one and two, 
respectively [50, 51]. IL-2, IL-12 and IFNs influence the differentiation of naïve T-cell precursors into 
their effector and memory populations and other cytokines may also contribute [50, 52]. 
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Co-stimulation is provided mainly by 4-1BB and CD27, although CD40, CD28 and OX40 can also 
contribute to signal 2 [5, 50]. Following clearance of antigen, IL-15 and IL-7 drive the proliferation 
and maintenance of the CD8+ memory populations and anti-apoptotic factors, such as BclXL, are 
essential to avoid activation-induced death of these cells [5, 53]. Here we show that modulation of 
NF-κB signalling by VACV protein N1 during primary infection affects the effector and memory 
CD8+ T-cell response, and this is consistent with NF-κB regulating the expression of many cytokines, 
co-stimulatory molecules and maintenance factors needed for CD8+ T-cell responses [54]. Transgenic 
mouse models for studying the impact of NF-κB on these processes are hampered by the profound 
effects on the development of haematopoietic cells and/or systemic hyperinflammation deriving from 
deletion or inhibition of NF-κB [55-57]. Hence, using mutant viruses to modify specific signalling 
pathways during infection provides an alternative way to assess the effects of NF-κB, or other 
inflammatory responses, on immunological memory development in a wild-type host. In addition, 
data produced in this study showed an unexpected specificity for enhancing CD8+ T-cell function 
without modulating CD4+ T-cell function to the same degree by direct modification of NF-κB during 
acute infection. In the future, mutant VACVs will allow aspects of the mechanisms of CD8+ and CD4+ 
T-cell responses during acute virus infection to be dissected.  
 
The impact of innate immunity on the development of immunological memory is of great interest for 
vaccine development. Adjuvants help memory development [28, 58] by activating pattern recognition 
receptors and thereby transcription factors, including NF-κB, which induce a favourable inflammatory 
cytokine environment at the site of antigen exposure during vaccination. The activity of N1 during 
VACV infection, namely blocking NF-κB and inhibiting CD8+ T-cell memory, is opposite to the 
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activity of a vaccine adjuvant. Therefore, deleting N1 from VACV is a logical strategy to improve 
immunogenicity, especially if cytotoxic T-cell activity is required. Indeed, removal of VACV 
immunomodulators can enhance memory responses during vaccination [26, 27, 59]. There are at least 
ten different VACV intracellular inhibitors of NF-κB activation [31-33, 60-67] and several other 
proteins that block IRF3 activation [23, 65, 67-69] and therefore it is likely that removal of some of 
these immunomodulators alone or in combination may improve immunological memory. Thus, these 
mutant viruses are valuable tools to identify factors promoting immunological memory as well as 
functioning as improved vaccines. 
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Figure legends 
Figure 1. N1 mutation does not affect splenic lymphocyte numbers following infection. Groups of 
5 mice were infected i.d. with the indicated VACVs and splenic lymphocyte populations were counted 
at 7, 14, 21 and 28 d p.i. (A, B) Total cell numbers. (C, D) T and B cell populations presented as total 
cell number (C) and as percentages of total lymphocytes (D). Results are expressed as mean ± SEM. 
Statistical comparison of cells from mock-infected mice with virus-infected mice: * p<0.05, ** 
p<0.01. 
 
Figure 2. Infection with vΔN1 or vN1.I6E induces enhanced numbers of effector CD8+ T-cells. 
Mice were infected i.d. with the indicated VACVs and populations of splenic GzmBhiCD62Llo
 
CD8+ 
T-cells were counted at 7, 14, 21 and 28 days p.i. (A) Flow cytometry scatter plots from representative 
samples from individual mice. The arrows emphasise the greater percentage of GzmBhiCD62Llo
 
CD8+ 
T-cells following infection with vN1.I6E or vΔN1 compared to other viruses. (B) Graphs showing the 
proportion of total CD8+ T-cells that were GzmBhiCD62Llo
 
(left) and the absolute numbers of 
GzmBhiCD62Llo cells (right panel) (mean ± SEM). *, p<0.05, n=5.  
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Figure 3. Infection with vΔN1 or vN1.I6E induces enhanced numbers of VACV-specific effector 
CD8+ T-cells. Mice were infected i.d. with the indicated VACVs and populations of splenic 
DimerX+CD8+, and GzmBhiCD62Llo of DimerX+CD8+ T-cells were counted at 7 days p.i. (A) Flow 
cytometry scatter plots from representative samples from individual mice. The arrows emphasise the 
greater percentage of DimerX+CD8+ and GzmBhiCD62Llo of Dimer+CD8+ T-cells following infection 
with vN1.I6E or vΔN1 compared to other viruses. (B) Graphs showing the absolute numbers of 
DimerX+CD8+ T-cells (left) and of GzmBhiCD62Llo cells (right panel) (mean ± SEM). *, p<0.05, n=5. 
 
Figure 4. Infection with vΔN1 or vN1.I6E induces enhanced numbers of effector CD8+ T-cells in the 
VACV-specific CD8+ T-cells in the draining lymph nodes. Mice were infected i.d. with the indicated 
VACVs and populations of DimerX+CD8+, and GzmBhiCD62Llo of DimerX+CD8+ T-cells in the draining 
lymph nodes were counted at 7 days p.i. (A) Flow cytometry scatter plots from representative samples 
from individual mice. The arrows emphasise the greater percentage of DimerX+CD8+ and GzmBhiCD62Llo 
of DimerX+CD8+ T-cells following infection with vN1.I6E or vΔN1 compared to other viruses. (B) Graphs 
showing the absolute numbers of DimerX+CD8+ T-cells (left) and GzmBhiCD62Llo of DimerX+CD8+ 
T-cells (right panel) (mean ± SEM). **, p<0.01, n=5. 
 
Figure. 5. VACVs lacking N1 or expressing I6E induce better protection to virus challenge. (A) 
Groups of 5 mice were infected i.d. with the indicated viruses. At 28 d p.i. mice were challenged i.n. 
with VACV (5×106 p.f.u of VACV WR) and weight change was monitored. Each mouse was 
compared to its original weight on day zero and data are expressed as the percentage ± SEM. (B) 
Groups of 5 mice were infected and challenged as (A), sacrificed on d 1 or 4 post challenge (p.c.) and 
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virus titres in the lungs were measured by plaque assay. Data are mean titre ± SEM, **,p<0.01. (C) 
Sera from mice infected as in (A) were collected 28 d p.i and assayed for neutralisation of VACV 
strain WR. The median value for each population is represented by a horizontal black bar. Significant 
differences between groups are shown, Mann–Whitney test. *, p<0.05, n=15. 
      
Figure 6. Deletion or I6E mutation of N1 enhances CD8+ T-cell cytotoxicity. (A) Mice were 
infected i.d. with the indicated viruses splenic lymphocytes were harvested at 28 d p.i. and tested for 
their ability to lyse VACV-infected EL4 cells by chromium release assay. Data are presented as 
percentage cell lysis at various effector to target (E:T) cell ratios. *, p<0.05, **, p<0.01, n=5. (B) 
Lymphocytes were prepared as in (A) and pre-incubated with a CD8 blocking mAb before cytotoxic 
activity was assayed as in (A). (C) Lymphocytes were prepared as in (A). Histograms showing the 
absolute number of CD8+ cells expressing CD107a following stimulation with VACV B8 peptide. (D) 
Cytotoxicity assay as in (A) but with purified splenic NK cells and using VACV-infected P815 cells as 
targets. Results are expressed as mean ± SEM.  
 
Figure 7. Deletion or I6E mutation of N1 enhances CD8+ TEM and TCM populations. Mice were 
infected i.d. with the indicated viruses and 28 d later populations of CD8+ or CD4+ CD44hiCD62Llo -
(TEM) and CD44hiCD62Lhi (TCM) cells were counted from (A) the spleen or (B) the draining lymph 
nodes. These data are presented as scatter plots with arrows indicating the gates corresponding to 
CD44hiCD62Llo
 
populations (black arrow) or CD44hiCD62Lhi (blue arrow, top panels), or as 
histograms showing absolute numbers of the specific populations as a proportion of total CD8+ or 
CD4+
 
cells. *, p<0.05, n=5. Results are expressed as mean ± SEM. 
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Figure 8. Deletion or I6E mutation of N1 enhances VACV-specific CD8+ TEM and TCM cell 
populations. Mice were infected i.d. with the indicated VACVs and populations of splenic lymphocytes 
that were DimerX+CD8+, and TEM or TCM of DimerX+CD8+ T-cells, were counted at 28 days p.i.. (A) Flow 
cytometry scatter plots from representative samples from individual mice. The arrows emphasise the 
greater percentage of DimerX+CD8+ following infection with vN1.I6E or vΔN1 compared to other viruses. 
(B) Graphs showing the absolute numbers of DimerX+CD8+ T-cells. (C) Graphs showing the absolute 
numbers of TEM and TCM of DimerX+CD8+ T-cells (mean ± SEM). *, p<0.05; **, p<0.01, n=5. 
 
Figure 9. Deletion or I6E mutation of VACV N1 enhances the effector function of memory CD8+ 
T-cells. Mice were infected i.d. with the indicated viruses and challenged i.n. 28 d p.i. with 5×106 
PFU of VACV WR. Lung or splenic lymphocytes were isolated 4 d later and the CD8+
 
T-cell 
populations were assayed by intracellular cytokine staining (ICS) for IFNγ production. Data are 
presented as scatter plots (top panels) and as histograms indicating the percentage of IFNγ+ CD8+
 
T-cells (middle panels), or the absolute cell number of IFNγ+ CD8+
 
T-cells (bottom panels). *, p<0.05, 
n=5. Results are expressed as mean ± SEM. 
 
Figure 10. CD8+ T-cells from vN1.I6E-infected mice confer enhanced protection. (A) Mice were 
infected i.d. with vN1.WT or vN1.I6E or mock infected and either CD8+ or CD4+ cells were isolated 
28 d p.i and 106 cells were transferred into naïve recipient mice. The recipient mice were challenged 6 
h later with 3×103 PFU. of VACV WR and weight change (middle panels) was monitored. *, p<0.05, 
n=5. Lower panels show virus titres in the lungs 5 d post challenge. Data are mean titre ± SEM, * 
p<0.05, ** p<0.01. NS = non-significant. (B) As (A), except the naïve recipient mice were depleted 
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for CD8+ or CD4+ T-cells by administration of mAb at 10, 8 and 6 d prior to transfer of cells. CD4+ 
T-cells were transferred to mice depleted of CD4+ T-cells, or CD8+ T-cells were transferred to mice 
depleted of CD8+ T-cells. *, p<0.05, n=5. Results are expressed as mean ± SEM. 
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